More woe for AspenBio with new AppyScore delay
This article was originally published in Clinica
AspenBio Pharma's 510(k) application for its troubled appendicitis blood test, AppyScore, looks likely to be delayed again. The company recently finished an expanded pivotal trial and had hoped to file the product with the US FDA in late June. However, it has now reported that it needs to carry out further analysis of the study results, as there was "unexplained variability" between sites. As a result, the Castle Rock, Colorado firm's share price on Nasdaq dropped by 54% on 7 June, closing at $1.57. This is not the first delay for AppyScore: AspenBio first submitted a 510(k) application in July 2009 based on disappointing results from a previous pivotal trial, but had to withdraw it in February and expand the study (www.clinica.co.uk, 10 February 2010).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.